TGTX 111
Alternative Names: TGTX-111; TSHA-111; TSHA-111-LAFORIN; TSHA-111-MALINLatest Information Update: 28 May 2024
Price :
$50 *
At a glance
- Originator University of Texas Southwestern Medical Center
- Developer Taysha Gene Therapies; University of Texas Southwestern Medical Center
- Class Antiepileptic drugs; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Lafora disease
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Lafora disease in USA (Intrathecal)
- 11 May 2021 Taysha Gene therapies plans IND/CTA submission for Lafora disease in 2021
- 01 Mar 2021 Pharmacodynamics data from preclinical studies in Lafora disease released by Taysha Gene Therapies